ADC Biotechnology Overview
- Year Founded
-
2010
- Status
-
Acquired/Merged
- Employees
-
62
- Latest Deal Type
-
M&A
ADC Biotechnology General Information
Description
Developer of new conjugation technologies designed to offer new antibody-drug conjugates. The company has developed a patented Lock-Release technology for the development and manufacture of the Antibody Drug Conjugates (ADC) group of cancer therapies which are designed to specifically target and kill tumor cells and also offer bioconjugation services, enabling physicians to treat patients with antibody-drug conjugate and anti-cancer therapies.
Contact Information
Website
www.adcbio.comCorporate Office
- 4 Friarsgate
- Whitefriars
- Chester CH1 1XG
- England, United Kingdom
Corporate Office
- 4 Friarsgate
- Whitefriars
- Chester CH1 1XG
- England, United Kingdom
ADC Biotechnology Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 13. Merger/Acquisition | 06-Apr-2021 | Completed | Generating Revenue | |||
| 12. Later Stage VC | 27-Mar-2020 | Completed | Generating Revenue | |||
| 11. Later Stage VC | 17-Jan-2020 | Completed | Generating Revenue | |||
| 10. Later Stage VC (Series D) | 14-Dec-2018 | Completed | Generating Revenue | |||
| 9. Later Stage VC | 20-Apr-2018 | Completed | Generating Revenue | |||
| 8. Debt - General | 19-Oct-2017 | Completed | Generating Revenue | |||
| 7. Grant | 25-Sep-2017 | Completed | Generating Revenue | |||
| 6. Later Stage VC | 21-Sep-2017 | Completed | Generating Revenue | |||
| 5. Later Stage VC | 01-Dec-2016 | $249K | $2M | Completed | Generating Revenue | |
| 4. Early Stage VC | 20-Dec-2012 | $1.11M | $1.75M | Completed | Generating Revenue |
ADC Biotechnology Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| C Ordinary | ||||||||
| C Ordinary | ||||||||
| C Ordinary | ||||||||
| C Ordinary | ||||||||
| A Ordinary | ||||||||
| B Ordinary | ||||||||
| C Ordinary | ||||||||
| C Ordinary | ||||||||
| C Ordinary | 35,765,056 | $0.000012 | $0.23 | $0.23 | 1x | $0.23 | 16.62% | |
| D Ordinary | 5,436,000 | $0.000012 | $0.23 | $0.23 | 1x | $0.23 | 2.53% |
ADC Biotechnology Comparisons
Industry
Financing
Details
ADC Biotechnology Competitors (49)
One of ADC Biotechnology’s 49 competitors is BioLegend, a Formerly Accelerator/Incubator backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| BioLegend | Formerly Accelerator/Incubator backed | San Diego, CA | ||||
| Eureka Therapeutics | Venture Capital-Backed | Emeryville, CA | ||||
| Oxford Biotherapeutics | Private Equity-Backed | Oxford, United Kingdom | ||||
| Macrogenics | Formerly VC-backed | Rockville, MD | ||||
| Gradalis | Private Equity-Backed | Carrollton, TX |
ADC Biotechnology Patents
ADC Biotechnology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-201617421-D0 | Medical device comprising derivatised support | Inactive | 14-Oct-2016 | ||
| GB-201518234-D0 | Medical device comprising derivatised support | Inactive | 15-Oct-2015 | ||
| JP-2017537975-A | Adcs synthesis method using affinity resin | Inactive | 28-Oct-2014 | ||
| GB-201419185-D0 | Method of synthesising adcs using affinity resin | Inactive | 28-Oct-2014 | ||
| CA-2965891-A1 | Method of synthesising adcs using affinity resins | Inactive | 28-Oct-2014 | C07K1/042 |
ADC Biotechnology Signals
ADC Biotechnology Former Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Bioscience Managers | Venture Capital | Minority | ||
| Denbighshire County Council | Government | |||
| Development Bank of Wales | Growth/Expansion | Minority | ||
| Downing | Asset Manager | Minority | ||
| Downing Ventures | Venture Capital | Minority |
ADC Biotechnology FAQs
-
When was ADC Biotechnology founded?
ADC Biotechnology was founded in 2010.
-
Where is ADC Biotechnology headquartered?
ADC Biotechnology is headquartered in Chester, United Kingdom.
-
What is the size of ADC Biotechnology?
ADC Biotechnology has 62 total employees.
-
What industry is ADC Biotechnology in?
ADC Biotechnology’s primary industry is Discovery Tools (Healthcare).
-
Is ADC Biotechnology a private or public company?
ADC Biotechnology is a Private company.
-
What is ADC Biotechnology’s current revenue?
The current revenue for ADC Biotechnology is .
-
How much funding has ADC Biotechnology raised over time?
ADC Biotechnology has raised $25.2M.
-
Who are ADC Biotechnology’s investors?
Bioscience Managers, Denbighshire County Council, Development Bank of Wales, Downing, and Downing Ventures are 5 of 8 investors who have invested in ADC Biotechnology.
-
Who are ADC Biotechnology’s competitors?
BioLegend, Eureka Therapeutics, Oxford Biotherapeutics, Macrogenics, and Gradalis are some of the 49 competitors of ADC Biotechnology.
-
When was ADC Biotechnology acquired?
ADC Biotechnology was acquired on 06-Apr-2021.
-
Who acquired ADC Biotechnology?
ADC Biotechnology was acquired by Sterling Pharma Solutions.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process